191 related articles for article (PubMed ID: 1616831)
21. Circulating complement levels and C3 glomerulopathy.
Fervenza FC; Sethi S
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1829-31. PubMed ID: 25341723
[No Abstract] [Full Text] [Related]
22. A hemolytic method for the measurement of nephritic factor.
West CD
J Immunol Methods; 2008 Jun; 335(1-2):1-7. PubMed ID: 18410942
[TBL] [Abstract][Full Text] [Related]
23. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
[TBL] [Abstract][Full Text] [Related]
24. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
[TBL] [Abstract][Full Text] [Related]
25. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up.
Schwertz R; Rother U; Anders D; Gretz N; Schärer K; Kirschfink M
Pediatr Allergy Immunol; 2001 Jun; 12(3):166-72. PubMed ID: 11473682
[TBL] [Abstract][Full Text] [Related]
26. [Partial lipodystrophy, hypocomplementemia and glomerulonephritis].
Habib R; Lévy M; Gubler MC; Broyer M; Habib M
Arch Fr Pediatr; 1977; 34(7 Suppl):CXCVII-CCXII. PubMed ID: 931525
[TBL] [Abstract][Full Text] [Related]
27. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
28. Serum terminal complement component levels in hypocomplementemic glomerulonephritides.
Clardy CW; Forristal J; Strife CF; West CD
Clin Immunol Immunopathol; 1989 Mar; 50(3):307-20. PubMed ID: 2917423
[TBL] [Abstract][Full Text] [Related]
29. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
[TBL] [Abstract][Full Text] [Related]
30. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
31. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
32. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
33. [Studies of complement, nephritic factor, and circulating immune complexes in chronic mesangiocapillary glomerulonephritis types I and II (author's transl)].
Mirapeix E; Yagüe J; Vives J; Revert L
Med Clin (Barc); 1981 Jun; 77(1):21-6. PubMed ID: 7253758
[TBL] [Abstract][Full Text] [Related]
34. C3 metabolism in acute glomerulonephritis: implications for sites of complement activation.
Endre ZH; Pussell BA; Charlesworth JA; Coovadia HM; Seedat YK
Kidney Int; 1984 Jun; 25(6):937-41. PubMed ID: 6236326
[TBL] [Abstract][Full Text] [Related]
35. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
36. Renal transplantation for patients with type I and type II membranoproliferative glomerulonephritis: serial complement and nephritic factor measurements and the problem of recurrence of disease.
Curtis JJ; Wyatt RJ; Bhathena D; Lucas BA; Holland NH; Luke RG
Am J Med; 1979 Feb; 66(2):216-25. PubMed ID: 371395
[TBL] [Abstract][Full Text] [Related]
37. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
38. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.
Sissons JG; Liebowitch J; Amos N; Peters DK
J Clin Invest; 1977 Apr; 59(4):704-15. PubMed ID: 845257
[TBL] [Abstract][Full Text] [Related]
39. The complement abnormalities of lipodystrophy.
Sissons JG; West RJ; Fallows J; Williams DG; Boucher BJ; Amos N; Peters DK
N Engl J Med; 1976 Feb; 294(9):461-5. PubMed ID: 1246331
[TBL] [Abstract][Full Text] [Related]
40. C3 nephritic factor and mesangiocapillary glomerulonephritis.
Williams DG
Pediatr Nephrol; 1997 Feb; 11(1):96-8. PubMed ID: 9035182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
